RecruitingPhase 2NCT04840264

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction


Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Enrollment

79 participants

Start Date

Jan 7, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a three-drug chemotherapy combination (docetaxel, oxaliplatin, and 5-FU) for patients with advanced stomach cancer who have developed a bowel blockage that cannot be treated with surgery. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with stomach or gastroesophageal cancer confirmed by biopsy - You have a bowel blockage (below the small intestine) caused by cancer spreading to the belly lining - Your blockage has been determined by two surgeons to be inoperable - Your blood counts, kidney, and liver function are adequate **You may NOT be eligible if:** - Your cancer has features that suggest different treatments may work better (HER-2 positive, high microsatellite instability) - You have active internal bleeding, severe heart or lung disease, or a brain infection from cancer - You are pregnant or breastfeeding - You have HIV or untreated active hepatitis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDocetaxel

25 mg/square metre, D1, D8, D15, repeat every 4 weeks.

DRUGOxaliplatin

85 mg/msquare metre, D1, D15, repeat every 4 weeks.

DRUGFluorouracil

1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.


Locations(1)

The Sixth Affiliated hosipital, Sun Yat-Sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04840264


Related Trials